ClinicalTrials.gg
Not yet recruitingNCT07687121AFROHINDU-MIGTUpdated Jul 7, 2026

Shaping a Community-based Pathway to Improve TB Surveillance Among African and Hindustan Immigrants Experiencing Vulnerabilities

An observational study in Tuberculosis, Tuberculosis (TB) and Tuberculosis Active, sponsored by Universidade Nova de Lisboa. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.

Primary conditionLatent TuberculosisRegistry: TuberculosisReclassifiedWhy we changed it
Registry
Tuberculosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Latent Tuberculosis
Why
  1. The study's listed conditions name Latent Tuberculosis, a narrower term within Tuberculosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Universidade Nova de Lisboa · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

This two-phase, mixed-methods approach project aims to develop a community-based, participatory, and co-created TB/TB infection (TBI) screening care pathway for African and Hindustan immigrants, who often face socioeconomic vulnerabilities and barriers to healthcare access, including TB/TBI screening. The first phase involves the co-design of a TB/TBI screening care pathway through four thematic workshops using the Double-Diamond theoretical framework. These workshops will engage key stakeholders, including immigrants, community leaders, healthcare professionals, and academics, to identify barriers, define needs, and develop actionable measures to improve TB/TBI screening care. The second phase involves a community-based study to implement the care pathway and estimate the incidence of TB and TBI among 200 immigrants from Angola, Cabo Verde, Guinea-Bissau, Mozambique, India, Bangladesh, and Nepal. Participants will be recruited through Grupcommunity services, and data will be collected on demographic, socioeconomic, health, and migration-related factors. The screening pathway will be implemented and evaluated, with patient-related outcomes measured to assess its effectiveness. The primary outcomes include the development of a culturally sensitive TB/TBI screening care pathway and the estimation of TB and TBI incidence among high-risk immigrant populations. Secondary outcomes include the profiling of immigrant populations, the identification of social vulnerabilities, and the establishment of eligibility criteria for TB/TBI screening in similar populations. We expected to advance knowledge on the specific needs of vulnerable immigrants regarding TB/TBI screening and care and to empower communities, improve access to healthcare, and inform policymakers on tailored prevention and control strategies. The findings will contribute to the global effort to eliminate TB by addressing the unique challenges faced by immigrant populations in low-incidence countries like Portugal.

Read the detailed description

Tuberculosis (TB) is an infectious disease primarily affecting the lungs but capable of spreading to other organs. Following infection, around 5% of those infected develop the disease in the first 2 years, while the others carry the bacteria but remain asymptomatic. TB infection (TBI) occurs when individuals are infected but do not show symptoms and are not contagious. In 2022, there were 10.6 million cases of TB, 1.3 million deaths due to TB worldwide and approximately 1.7 billion people globally were estimated to have TBI, representing a significant pool of potential future TB cases. Preventive treatment for TBI is crucial to reducing the risk of progression to active TB and is a key component of the World Health Organization's (WHO) End TB Strategy. Early diagnosis, effective treatment, and targeted interventions for groups at increased risk are essential to controlling both TB and TBI globally.

The number of TB cases in Portugal has been gradually decreasing. In 2016 the country was considered a low-incidence country (\<20 TB cases per 100,000 inhab). Immigrants are among the groups experiencing higher TB burden, especially in low-incidence countries, dure to factors such as overcrowding, poor living conditions, and limited healthcare access during migration trajectory and in refugee camps. Immigrants accounted for 30.1% of TB cases in Portugal in 2022, with a notification rate 4 times higher than the national average (58.5 cases/100,000 inhab). The majority of TB cases in immigrants were from Angola, Brazil, Guinea-Bissau, and Cape Verde. In 2023, the number of immigrants increased by 34% compared to 2022 with more than a million documented immigrants living in the country and an estimated number of undocumented immigrants between 30,000 and 50,000. Seven of the nine most common nationalities of newly arrived immigrants are from high TB burden regions like Africa and Hindustan, i.e., Angola, Cape Verde, India, Guinea Bissau, Bangladesh and Nepal.

In Portugal, the current guidelines for TB surveillance and management identify immigrants as one of the key populations for targeted intervention and establish those from high incidence countries (i.e., Angola, Guinea-Bissau, Cabo Verde, Mozambique, Ukraine, Romania and Russia) should be screened. However, immigrants from Hindustan countries are not included despite growing significance in current immigration trends.

The overall aims of this project are to develop a community based, participatory, co-created TB/ TBI screening care path, to estimate the incidence of TB and TBI in African and Hindustan immigrants in Portugal and to understand how some of their social, health and economic vulnerabilities may influence TB risk and adherence to a cascade of TB/TBI screening care.

Aim: to develop a co-created TB/TBI screening care path to ensure immigrants are not left behind and that no one is left untreated.

A two-phase sequential, mixed-methods approach was designed. The first phase pertains to i) Co-Creation of a TB/TBI Screening Care Path: Developing a culturally sensitive TB/TBI screening care pathway for immigrants; and the second phase to ii) Care in Motion: Community-Based Study: Implementing and evaluating the care path through a community-based survey.

i) Co-Creation of a TB/TBI Screening Care Path: Developing a culturally sensitive TB/TBI screening care pathway for immigrants Phase I will bring together the team and stakeholders closely involved in the research project, particularly from community services and TB dedicated health services to review the team's principles, clarify members' roles, identify bottlenecks and facilitators, and discuss the team's vision for the future. This vision will focus on what the team aims to achieve regarding TB and TBI screening among immigrants. This initial step will help the team "see the bigger picture" and position the team to work differently. It will also facilitate a more effective and holistic mapping of existing and potential stakeholders to include in the co-creation process. The outcomes of this activity (team roles, future vision, and stakeholder mapping) will support the following four thematic workshops (WS): WS1 Discover, WS2 Define, WS3 Develop, and WS4 Deliver.

All stakeholders identified in the stakeholder mapping exercise will be invited to participate in the four workshops. The workshops will take place in an open, friendly, and safe environment where everyone feels free to participate. Discussions will be guided using a semi-structured script to direct the conversation. All participants will be invited to share their views in turn, ensuring a more inclusive experience.

In WS1, a root cause analysis will be used to systematically explore events (what happens), patterns (trends), structures (what enables patterns and trends to persist), and mental models (what makes these structures possible) related to TB and TBI screening among immigrants. Building on the results of WS1, in WS2 the problem under analysis will be reframed, challenging the current way of thinking. This will be done using a different perspectives approach (e.g., how to change the approach, what might be possible, what might be difficult). In WS3, stakeholders will be invited to create a series of new and innovative activities concerning TB and TBI among immigrants, with a particular focus on surveillance care, using a portfolio of ideas. Finally, in WS4, the prototype for the TB/TBI screening care pathway for immigrants will be developed, incorporating ideas that emerged during the previous workshops. To accomplish this, a Radical Innovations approach will be used.

ii) Care in Motion: Community-Based Study: Implementing and evaluating the care path through a community-based survey In the second phase of the project, the co-created TB/TBI screening pathway will be implemented. Community researchers will be recruited and will work closely with community services working with the targeted population. These researchers will be responsible for recruiting participants, collecting data and guiding participants through the TB/TBI care path, and will primarily be selected from the African and Hindustan communities. If feasable, recruitment will take place before the workshops of phase 1, allowing these researchers to also participate in the co-creation process. Researchers from the African community will need to speak Portuguese and Creole, while researchers from the Hindustan community will need to speak English and one or more of the following languages: Hindi, Urdu, Nepali, or Bengali. This linguistic diversity aims to reduce language barriers during the implementation of the TB/TBI screening pathway. Community researchers will receive training from the research team on the screening pathway and data collection procedures.

Over a 6-month period, 200 participants will be consecutively be recruited among users of the community services. These participants will be invited to take part in the TB/TBI screening pathway. The number of participants has been determined based on the capacity of the TB dedicated health care services to conduct TB/TBI screenings for all participants within the study period, as well as to provide treatment as necessary. Participants must be 18 years or older, have started their migration journey less than 5 years ago, and be nationals from Angola, Cabo Verde, Guinea-Bissau, Mozambique, India, Bangladesh, or Nepal. Immigrants with a legally designated representative will be excluded from the study.

Upon signing the informed consent form, participants will begin the TB/TBI screening care pathway. An electronic survey designed in RedCap to collect data on demographic and socio-economic characteristics, living and housing conditions, migration journey, clinical and epidemiological profile, substance use, and TB/TBI risk will be used. All participants will be invited to follow the TB/TBI screening pathway and will be offered IGRA test at TB dedicated health services as well as other medical exams needed to confirm or further study their clinical condition and according to their needs. Participants diagnosed with TB/TBI during the study will be treated by the TB dedicated health service according to Portuguese National Guidelines.

Primary outcomes: Incidence of TB and TBI, Performance of TB/TBI risk questionnaires relative to screening tests, Immigrant-related outcomes Secondary outcomes: Immigrant profile (demographic, socio-economic, migration journey, health), Prevalence of other social vulnerabilities This project will allow first glimpse of some of the socioeconomic and health issues faced by the African and Hindustan immigrant community. It utilizes a culturally adequate and participatory methodology to address a problem identified by relevant stakeholders and will co-create a solution, boosting communities' awareness and empowerment, as well as partners' responsiveness towards TB prevention.

02

Conditions studied

  • Tuberculosis
  • Tuberculosis (TB)
  • Tuberculosis Active
  • Tuberculosis Infection, Latent

Browse trials for

Keywords

  • Immigrants
  • Migrants
  • Tuberculosis
  • Surveillance
  • Screening
  • Care pathway
03

In context

Latent Tuberculosis Reclassified

199 studies on the registry are indexed under Latent Tuberculosis; 48 are open to participants now.

This study's planned enrollment of 200 is below the median of 260 across 82 observational studies indexed under Latent Tuberculosis.

Browse Latent Tuberculosis studies →

Lead sponsor

Universidade Nova de Lisboa is the lead sponsor of 43 studies on the registry; 12 are open to participants now.

Compared within Latent Tuberculosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We will use a sequential non-probability sampling method. Eligible participants will be recruited consecutively from community services in Lisbon and associated community networks during the defined data collection period, until the planned sample size is reached or until the end of the recruitment period (6 months after the first workshop).

We plan to include approximately 200 participants. This sample size was determined by the operational capacity of the services involved, specifically capacity for community recruitment and participant follow-up, and the capacity of the TB community services for clinical evaluation, diagnosis, treatment decisions, and follow-up when necessary.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- adult immigrants, aged 18 years or older, from Angola, Cape Verde, Guinea-Bissau, Mozambique, India, Bangladesh, or Nepal, who began their migration journey less than five years ago, who attend or are identified through community services or associated community networks, and who agree to participate by signing an form.

Exclusion criteria

Exclusion Criteria:

  • Participants with a legally appointed representative
  • Participants incapable of understanding essential study information, even with linguistic or cultural mediation support and with any clinical condition that prevents the interview, , or screening process
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Immigrants

    Immigrants in Portugal that have started migration journey less than 5 years before the data collcetion for the study, originated from Angola, Mozambique, Guinea Bissau, Cape Verde, Bangladesh, India or Nepal

06

What researchers measure

Primary outcomes

  1. Incidence of TB

    Number of TB positive immigrants / Total immigrants screened

    Time frame: Baseline

  2. Incidence of TB infection

    Number of participants positive for TB infection / All participants screened

    Time frame: Baseline

Secondary outcomes

  1. Immigrant profile

    SE and demographic characteristics of immigrants, migration journey, general health and wellbeing, prevalence of social vulneraibilities

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Direção Geral da Saúde. (2023). Guia Cuidados de Saúde em Tuberculose para Populações Vulneráveis . Direção Geral da Saúde. https:// www.dgs.pt/tuberculose/ficheiro-de-registos-folhetos/guia-tb-populacoes-vulneraveis_mar2023-pdf.aspx
  • Direção Geral da Saúde. (2022). Recomendações de rastreio de Tuberculose em cidadãos provenientes de paises de alta incidência de TB . https://www.chporto.pt/images/noticias/2022/ Recomendac__o__es_de_rastreio_de_Tuberculose_em_cidada__os_provenientes_de_paises_de_alta_incide__ncia_de_TB.pdf

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jul 7, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07687121
Lead sponsor
Universidade Nova de Lisboa
Collaborators
NOVA National School of Public Health
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Ines Fronteira, PhD
Contact
ines.fronteira@ensp.unl.pt
+351215712100
Ines Fronteira, PhD
principal investigator · NOVA National School of Public Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion